notice Published 2025-12-22

Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Institution of Investigation

Origins: CH

📌 ETDETA brief — importer impact summary (educational)

Brief takeaway: The ITC has been asked to investigate whether certain imported antibody drug conjugates involve misappropriated trade secrets, which could lead to import bans on affected products.

What changed: According to the notice, a Section 337 complaint was filed on November 18, 2025 (supplemented December 10, 2025) by AbbVie Inc., ImmunoGen, Inc., and ImmunoGen Switzerland GmbH. The notice states the complaint alleges that importation of certain antibody drug conjugates and components thereof, and products containing them, involves misappropriation of trade secrets that threatens or injures a U.S. industry. The notice says complainants request a limited exclusion order and cease and desist orders.

Who's affected: The notice names certain antibody drug conjugates, their components, and products containing them. It names complainants located in Illinois, Massachusetts, and Switzerland; the source cites Switzerland (CH) among affected origins. No HTS codes are specified in the notice.

What to review:
- Review whether your imported products fall within the described antibody drug conjugates, components, or products containing them.
- Check the complaint (excluding confidential material) on the ITC's EDIS docket for scope details.
- Confirm with your broker or trade counsel whether a potential exclusion or cease and desist order could reach your shipments.
- Review your supply chain sourcing, including any Switzerland-linked suppliers, for potential exposure.

This is general information, not legal advice and not a compliance determination — confirm specifics with a licensed customs broker or trade counsel.

Official notice

Notice is hereby given that a complaint filed with the U.S. International Trade Commission on November 18, 2025, under section 337 of the Tariff Act of 1930, as amended, on behalf of AbbVie Inc. of North Chicago, Illinois; ImmunoGen, Inc. of Waltham, Massachusetts; and ImmunoGen Switzerland GmbH. A letter supplementing the complaint was filed on December 10, 2025. The complaint alleges violations of section 337 based upon the importation into the United States of certain antibody drug conjugates and components thereof and products containing the same by reason of misappropriation of trade secrets the threat or effect of which is to destroy or substantially injure an industry in the United States or to prevent the establishment of an industry in the United States. The complainants request that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders. Addresses: The complaint, except for any confidential information contained therein, may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email [email protected]. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205- 2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov.

Source: Federal Register · International Trade Commission · Read the official notice ↗

Check how this affects your product

Run a U.S. import compliance self-check → Check an HTS classification → Estimate duty & landed cost →

Need help moving this shipment?

ETDETA coordinates the logistics side of your U.S. import — booking, ocean freight, inland transportation, and customs-clearance coordination through licensed customs brokers.

Get a Full Freight Quote →

Related updates

This update is a general educational summary based on public CBP CSMS / Federal Register information. It is not legal advice, customs broker advice, a final classification, duty determination, entry instruction, or compliance determination. Importers should confirm applicability, effective dates, HTSUS/Chapter 99 reporting, rates, refunds, PSC procedures, and filing instructions with their licensed customs broker, trade counsel, and/or CBP.